Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
[forminator_form id="25163"]

news.illinoisgenengnews+1genengnewsResearchers at the University of Illinois Urbana-Champaign have demonstrated that a precision gene-editing tool can reduce the toxic protein burden and neurological symptoms of Huntington's disease in mice — not by silencing the gene, but by subtly rewriting how it is read.
The study, published in Nature Biomedical Engineering on July 29, represents a departure from previous gene-therapy approaches that aimed to turn off the huntingtin (HTT) gene entirely. Instead, the team led by Pablo Perez-Pinera and Thomas Gaj, professors of bioengineering, designed CRISPR base editors that chemically convert a single DNA base without cutting both strands of the double helix. The edit causes the cell's machinery to skip over a small section of the gene — exon 13 — that encodes sites where the protein is cleaved into neurotoxic fragments.genengnews+2
"Instead of inactivating the protein completely or targeting collateral pathways, we introduce a very small edit in the gene that changes how the protein is processed by the cells," Perez-Pinera said. "For Huntington's disease, this is an exciting development because there is no cure and having multiple possible treatments in the pipeline provides a reason for hope."news.illinois
The team screened more than 140 base editors to find candidates with the best balance of on-target efficiency and minimal off-target effects. The lead editors were delivered via adeno-associated viruses directly into the brains of mice carrying mutant HTT genes. Treated animals accumulated fewer toxic huntingtin fragments, displayed reduced disease-associated symptoms, and showed less brain degeneration compared with untreated controls.bioengineer+1
"Our base editors were developed to target the region of HTT that, when cleaved, can initiate the chain of events that leads to the toxic fragments," Gaj said. "The result is that instead of turning the protein off completely, we alter how the gene is read so that the most damaging protein fragments are not produced."news.illinois
The researchers plan to evaluate their lead editors in humanized mouse models to assess tolerability and determine whether editing reduces normal HTT below a safe threshold. They also intend to test across a range of doses in large animals to define a therapeutic window. Longer-term goals include making delivery to the brain less invasive and less reliant on viral vectors, and adapting the approach to target other toxic regions of the HTT protein.genengnews+2
Approximately 41,000 people in the United States have symptomatic Huntington's disease, with more than 200,000 at risk of inheriting the condition. No cure currently exists.genengnews